Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EWTX Edgewise Therapeutics	$14.85 +1.6%	$13.79	$10.60 ▼ $38.12	$1.54B	0.26	664,563 shs	570,322 shs
GTHX G1 Therapeutics	$7.15	$7.13	$1.08 ▼ $7.19	$373.81M	1.66	1.70 million shs	N/A
JANX Janux Therapeutics	$24.30 +1.3%	$24.51	$21.97 ▼ $71.71	$1.44B	2.86	923,446 shs	703,678 shs
SDGR Schrodinger	$20.32 +3.8%	$20.66	$16.60 ▼ $28.47	$1.44B	1.67	1.39 million shs	1.90 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EWTX Edgewise Therapeutics	+1.57%	+4.95%	+3.20%	+4.50%	-29.08%
GTHX G1 Therapeutics	0.00%	0.00%	0.00%	0.00%	+0.70%
JANX Janux Therapeutics	+1.25%	-3.23%	-8.16%	-3.65%	-45.88%
SDGR Schrodinger	+3.78%	+4.85%	-11.77%	-5.05%	+1.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EWTX Edgewise Therapeutics	2.3289 of 5 stars	3.5	2.0	0.0	0.0	2.4	2.5	0.0
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	2.0957 of 5 stars	3.5	3.0	0.0	0.0	1.2	1.7	0.0
SDGR Schrodinger	3.0987 of 5 stars	3.3	3.0	0.0	0.0	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EWTX Edgewise Therapeutics	2.91	Moderate Buy	$40.55	173.03% Upside
GTHX G1 Therapeutics	0.00	N/A	N/A	N/A
JANX Janux Therapeutics	3.08	Buy	$86.90	257.61% Upside
SDGR Schrodinger	2.67	Moderate Buy	$27.83	36.98% Upside

Current Analyst Ratings Breakdown

Latest GTHX, JANX, EWTX, and SDGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $30.00
8/18/2025	JANX Janux Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
8/18/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $19.00
8/15/2025	SDGR Schrodinger	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$35.00 ➝ $20.00
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/8/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$48.00 ➝ $49.00
7/30/2025	EWTX Edgewise Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$46.00
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$5.59 per share	N/A
GTHX G1 Therapeutics	$58.20M	6.42	N/A	N/A	$0.68 per share	10.51
JANX Janux Therapeutics	$10.59M	137.88	N/A	N/A	$16.48 per share	1.47
SDGR Schrodinger	$207.54M	7.21	N/A	N/A	$4.66 per share	4.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EWTX Edgewise Therapeutics	-$133.81M	-$1.55	N/A	N/A	N/A	N/A	-30.65%	-29.18%	11/6/2025 (Estimated)
GTHX G1 Therapeutics	-$47.97M	-$0.62	N/A	N/A	N/A	-76.93%	-136.98%	-39.33%	N/A
JANX Janux Therapeutics	-$68.99M	-$1.80	N/A	N/A	N/A	N/A	-11.48%	-11.01%	11/5/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.48	N/A	N/A	N/A	-76.22%	-45.70%	-24.81%	N/A

Latest GTHX, JANX, EWTX, and SDGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	EWTX Edgewise Therapeutics	-$0.42	-$0.34	+$0.08	-$0.34	N/A	N/A
8/7/2025	Q2 2025	JANX Janux Therapeutics	-$0.48	-$0.55	-$0.07	-$0.55	$0.30 million	N/A
8/6/2025	Q2 2025	SDGR Schrodinger	-$0.83	-$0.59	+$0.24	-$0.59	$52.03 million	$54.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EWTX Edgewise Therapeutics	N/A	28.87	28.87
GTHX G1 Therapeutics	1.34	2.48	2.12
JANX Janux Therapeutics	N/A	47.03	47.03
SDGR Schrodinger	N/A	3.30	3.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EWTX Edgewise Therapeutics	N/A
GTHX G1 Therapeutics	24.21%
JANX Janux Therapeutics	75.39%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
EWTX Edgewise Therapeutics	23.20%
GTHX G1 Therapeutics	6.11%
JANX Janux Therapeutics	8.10%
SDGR Schrodinger	21.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EWTX Edgewise Therapeutics	60	105.35 million	80.91 million	Optionable
GTHX G1 Therapeutics	170	52.28 million	49.09 million	Optionable
JANX Janux Therapeutics	30	60.09 million	55.23 million	Optionable
SDGR Schrodinger	790	73.61 million	58.15 million	Optionable

GTHX, JANX, EWTX, and SDGR Headlines

Recent News About These Companies

Schrödinger: A Complex Story With Many Moving Parts

August 21 at 12:27 PM | seekingalpha.com

Public Sector Pension Investment Board Raises Stake in Schrodinger, Inc. $SDGR

August 21 at 3:51 AM | marketbeat.com

Cetera Investment Advisers Takes Position in Schrodinger, Inc. $SDGR

August 21 at 3:08 AM | marketbeat.com

Morgan Stanley Cuts Schrodinger (NASDAQ:SDGR) Price Target to $19.00

August 20 at 10:33 AM | marketbeat.com

Morgan Stanley Issues Pessimistic Forecast for Schrodinger (NASDAQ:SDGR) Stock Price

August 20 at 2:25 AM | americanbankingnews.com

What 4 Analyst Ratings Have To Say About Schrodinger

August 18, 2025 | benzinga.com

Tocqueville Asset Management L.P. Sells 23,590 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

August 18, 2025 | marketbeat.com

Schrodinger, Inc. (NASDAQ:SDGR) Receives $31.20 Consensus Price Target from Analysts

August 18, 2025 | americanbankingnews.com

Schrodinger (NASDAQ:SDGR) Shares Gap Down - Should You Sell?

August 17, 2025 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Upgraded to Strong-Buy at Barclays

August 17, 2025 | marketbeat.com

Tejara Capital Ltd Has $2.65 Million Holdings in Schrodinger, Inc. (NASDAQ:SDGR)

August 17, 2025 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Shares Gap Down - Time to Sell?

August 17, 2025 | americanbankingnews.com

Schrodinger (NASDAQ:SDGR) Earns Overweight Rating from Analysts at Barclays

August 17, 2025 | americanbankingnews.com

Schrodinger (SDGR) Gets a Buy from Barclays

August 16, 2025 | theglobeandmail.com

Craig-Hallum Sticks to Its Buy Rating for Schrodinger (SDGR)

August 16, 2025 | theglobeandmail.com

Schrodinger (NASDAQ:SDGR) Sets New 12-Month Low - Here's What Happened

August 16, 2025 | marketbeat.com

Schrodinger downgraded at Citi after clinical program exit

August 16, 2025 | msn.com

Citigroup Downgrades Schrödinger (SDGR)

August 16, 2025 | msn.com

Schrodinger, Inc. (NASDAQ:SDGR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 16, 2025 | marketbeat.com

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 15, 2025 | businesswire.com

Barclays Initiates Coverage of Schrödinger (SDGR) with Overweight Recommendation

August 15, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTHX, JANX, EWTX, and SDGR Company Descriptions

Edgewise Therapeutics NASDAQ:EWTX

$14.85 +0.23 (+1.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$14.78 -0.06 (-0.44%)

As of 08/22/2025 06:11 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

G1 Therapeutics NASDAQ:GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Janux Therapeutics NASDAQ:JANX

$24.30 +0.30 (+1.25%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$24.12 -0.18 (-0.72%)

As of 08/22/2025 05:25 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Schrodinger NASDAQ:SDGR

$20.32 +0.74 (+3.78%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$19.95 -0.37 (-1.82%)

As of 08/22/2025 07:34 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time